More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I New European Valvular Heart Disease Guidelines <ul> <li>2025 ESC/EACTS Guidelines for the management of valvular heart disease  https://doi.org/10.1093/eurheartj/ehaf194</li> <li>Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/</li> <li>Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528</li> <li>Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336</li> </ul> II  New Drug for Resistant HTN <ul> <li>Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7</li> </ul> <ul> <li>Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109</li> <li>Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440</li> </ul> III HCM News at ESC <ul> <li>New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv</li> </ul> <ul> <li>MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654</li> <li>SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424</li> <li>ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927</li> </ul> IV Vericiguat at ESC <ul> <li>New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9</li> </ul> <ul> <li>VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4</li> <li>VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928</li> <li>An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4</li> </ul> V More on Digoxin <ul> <li>RATE AF substudy https://doi.org/10.1002/ejhf.70022</li> <li>Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407</li> <li>Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8</li> </ul> You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Sep 12 2025 This Week in Cardiology

This Week in Cardiology

AI Chapters

AI Insights

Reviews